Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.72
+0.52 (0.84%)
At close: Dec 19, 2025, 4:00 PM EST
62.05
-0.67 (-1.07%)
After-hours: Dec 19, 2025, 7:59 PM EST
Cytokinetics Employees
Cytokinetics had 498 employees as of December 31, 2024. The number of employees increased by 75 or 17.73% compared to the previous year.
Employees
498
Change (1Y)
75
Growth (1Y)
17.73%
Revenue / Employee
$175,122
Profits / Employee
-$1,509,928
Market Cap
7.67B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 498 | 75 | 17.73% |
| Dec 31, 2023 | 423 | 14 | 3.42% |
| Dec 31, 2022 | 409 | 156 | 61.66% |
| Dec 31, 2021 | 253 | 69 | 37.50% |
| Dec 31, 2020 | 184 | 28 | 17.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CYTK News
- 1 day ago - US FDA approves Cytokinetics' heart disease drug - Reuters
- 1 day ago - Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms - GlobeNewsWire
- 3 days ago - Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 4 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 8 days ago - Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 16 days ago - 3 Potential Mid-Cap Biotech Buyout Targets In 2026 - Seeking Alpha
- 4 weeks ago - Cytokinetics: A Heavily Mispriced Cardiovascular Platform - Seeking Alpha
- 4 weeks ago - Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy - GlobeNewsWire